Skip to main content

Table 7 Active Phase III clinical trials with novel therapeutic drugs in mRCC

From: Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma

NCT name Drug/procedure combinations Primary outcome
NCT03055013
PROSPER
Nephrectomy vs. Perioperative Nivolumab RFS
NCT03592472
RENAVIV
Pazopanib + Placebo vs. Pazopanib + Abexinostat PFS
NCT03260894 Sunitinib/Pazopanib vs. Pembrolizumab + Epacadostat ORR
NCT03288532
RAMPART
Durvalumab vs Durvalumab + Tremelimumab DFS
NCT03142334 Pembrolizumab (Adjuvant setting) DFS
NCT03138512
CheckMate 914
Nivolumab + Ipilimumab (Adjuvant setting) DFS
NCT03091192 Savolotinib vs. Sunitinib PFS
NCT03024996
IMmotion 010
Atezolizumab (Adjuvant setting) DFS